A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors
暂无分享，去创建一个
H. Lane | A. Stathis | C. Sessa | M. Joerger | M. Engelhardt | D. Hess | M. Volden | T. Kaindl | P. Larger | Y. Metaxas | M. Mark | M. Mantiero | R. von Moos | N. Lévy | Peter Hafner | Silvia Stuedeli